D. E. Shaw & Co., Inc. Ultragenyx Pharmaceutical Inc. Transaction History

D. E. Shaw & Co., Inc.

$100 Billion
Q1 2025

A detailed history of D. E. Shaw & Co., Inc. transactions in Ultragenyx Pharmaceutical Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 556,417 shares of RARE stock, worth $20.6 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

556,417

Previous 286,079 94.5%

Holding current value

$20.6 Million

Previous $12 Million 67.4%

% of portfolio

0.02%

Previous 0.01%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2025 May 15, 2025	BUY	$36.21 - $45.78 $9.79 Million - $12.4 Million	270,338 Added 94.5%	556,417 $20.1 Million
Q4 2024 Feb 14, 2025	BUY	$42.07 - $57.72 $1.03 Million - $1.41 Million	24,485 Added 9.36%	286,079 $12 Million
Q3 2024 Nov 14, 2024	BUY	$40.21 - $59.36 $2.34 Million - $3.45 Million	58,152 Added 28.58%	261,594 $14.5 Million
Q2 2024 Aug 14, 2024	BUY	$37.42 - $51.61 $7.61 Million - $10.5 Million	203,442 New	203,442 $8.36 Million
Q3 2023 Nov 14, 2023	SELL	$34.92 - $46.66 $3.1 Million - $4.14 Million	-88,777 Reduced 93.52%	6,152 $219,000
Q2 2023 Aug 14, 2023	SELL	$37.35 - $52.15 $969,568 - $1.35 Million	-25,959 Reduced 21.47%	94,929 $4.38 Million
Q1 2023 May 15, 2023	SELL	$36.99 - $48.71 $6.26 Million - $8.24 Million	-169,107 Reduced 58.31%	120,888 $4.85 Million
Q4 2022 Feb 14, 2023	SELL	$33.72 - $46.33 $6.15 Million - $8.45 Million	-182,359 Reduced 38.61%	289,995 $13.4 Million
Q3 2022 Nov 14, 2022	BUY	$39.96 - $66.14 $4.51 Million - $7.46 Million	112,837 Added 31.39%	472,354 $19.6 Million
Q2 2022 Aug 15, 2022	SELL	$45.8 - $85.4 $5.72 Million - $10.7 Million	-124,821 Reduced 25.77%	359,517 $21.4 Million
Q1 2022 May 16, 2022	SELL	$62.2 - $84.4 $3.87 Million - $5.25 Million	-62,253 Reduced 11.39%	484,338 $35.2 Million
Q4 2021 Feb 14, 2022	BUY	$73.71 - $87.86 $5.22 Million - $6.23 Million	70,884 Added 14.9%	546,591 $46 Million
Q3 2021 Nov 15, 2021	SELL	$77.92 - $102.4 $22.6 Million - $29.7 Million	-290,390 Reduced 37.91%	475,707 $42.9 Million
Q2 2021 Aug 16, 2021	BUY	$92.19 - $115.71 $1.38 Million - $1.73 Million	14,929 Added 1.99%	766,097 $73 Million
Q1 2021 May 17, 2021	BUY	$106.9 - $167.73 $3.84 Million - $6.02 Million	35,881 Added 5.02%	751,168 $85.5 Million
Q4 2020 Feb 16, 2021	BUY	$84.4 - $177.39 $24 Million - $50.4 Million	284,395 Added 66.0%	715,287 $99 Million
Q3 2020 Nov 16, 2020	BUY	$72.98 - $90.0 $6.84 Million - $8.44 Million	93,728 Added 27.8%	430,892 $35.4 Million
Q2 2020 Aug 14, 2020	SELL	$46.91 - $78.22 $2.88 Million - $4.8 Million	-61,310 Reduced 15.39%	337,164 $26.4 Million
Q1 2020 May 15, 2020	BUY	$33.8 - $62.9 $2.85 Million - $5.3 Million	84,306 Added 26.83%	398,474 $17.7 Million
Q4 2019 Feb 14, 2020	BUY	$36.08 - $45.83 $4.54 Million - $5.76 Million	125,785 Added 66.77%	314,168 $13.4 Million
Q3 2019 Nov 14, 2019	BUY	$42.5 - $63.11 $2.33 Million - $3.46 Million	54,777 Added 41.0%	188,383 $8.06 Million
Q2 2019 Aug 14, 2019	SELL	$54.93 - $74.36 $580,665 - $786,059	-10,571 Reduced 7.33%	133,606 $8.48 Million
Q1 2019 May 15, 2019	SELL	$39.87 - $69.36 $7.08 Million - $12.3 Million	-177,657 Reduced 55.2%	144,177 $10 Million
Q4 2018 Feb 14, 2019	BUY	$38.89 - $77.3 $12.3 Million - $24.5 Million	316,434 Added 5859.89%	321,834 $14 Million
Q3 2018 Nov 14, 2018	BUY	$71.81 - $90.15 $387,774 - $486,810	5,400 New	5,400 $412,000
Q4 2017 Feb 14, 2018	SELL	$43.54 - $57.32 $552,174 - $726,932	-12,682 Closed	0 $0
Q3 2017 Nov 14, 2017	BUY	$49.79 - $66.32 $631,436 - $841,070	12,682	12,682 $675,000

Others Institutions Holding RARE

# of Institutions

336

Shares Held

88.9M

Call Options Held

1.08M

Put Options Held

1.04M

View Full List

About Ultragenyx Pharmaceutical Inc.

Ticker RARE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 70,036,896
Market Cap $2.59B
Description
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast...

More about RARE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.

Account